Clinical DataResearch Only
Retatrutide Dosing Guide
Evidence-based dosing protocols across 1 administration approach.
Medical Disclaimer
This dosing information is for educational reference only. Dosing decisions require physician oversight. Do not self-prescribe or adjust dosing without consulting a qualified healthcare provider.
Dosing Protocols
Phase 2 Obesity Trial
Clinical TrialSubcutaneousDose Range
1–12 mg
Frequency
weekly
Source
Phase 2 NEJM; TRIUMPH Phase 3 program
Escalation Schedule
Wk 1-4: 2 mg → Wk 5-8: 4 mg → Wk 9-12: 6 mg → Wk 13-16: 9 mg → Wk 17+: 12 mg
Triple GIP/GLP-1/glucagon agonist. 24.2% weight loss at 12 mg (48 wk). Not FDA-approved.
Administration
Delivery methods
Subcutaneous injection
⏳
Pending physician review — consult your provider before use.Updated 2026-04-10